Neuralink Secures $650M Series E Funding to Advance Brain-Computer Trials
Neuralink, Elon Musk’s neurotechnology venture, has closed a $650 million Series E funding round, propelling its valuation to $9 billion. The capital will accelerate human trials for its brain-computer interface (BCI) technology across the U.S., Canada, and UAE. FDA approvals have already enabled paralyzed patients to communicate via thought-controlled implants.
Investors including ARK Invest, Sequoia Capital, and Founders Fund backed the round. Neuralink’s breakthroughs in speech and vision restoration are now transitioning from lab to clinic, with real-world demonstrations showcasing unprecedented patient outcomes.